Brief: Daré Bioscience Announces Positive Efficacy Results From The Dare-Hrt1 Phase 1 / 2 Study

Dare Bioscience

17/10/2022 13:27

Oct 17 (Reuters) - Dare Bioscience Inc  DARE.O :
    * DARÉ BIOSCIENCE ANNOUNCES POSITIVE EFFICACY RESULTS FROM
THE
DARE-HRT1 PHASE 1 / 2 STUDY
    * DARÉ BIOSCIENCE ANNOUNCES POSITIVE EFFICACY RESULTS FROM
DARE-HRT1 PHASE 1 / 2 STUDY
    * DARE BIOSCIENCE INC - STATISTICALLY SIGNIFICANT RESULTS
FOR
IMPROVEMENT IN BOTH VASOMOTOR AND VAGINAL SYMPTOMS OF MENOPAUSE
    * DARE BIOSCIENCE INC - STUDY TREATMENT WAS WELL TOLERATED
WITH
TYPES OF MOST COMMON ADVERSE EVENTS CONSISTENT WITH OTHER
VAGINAL PRODUCTS
    * DARE BIOSCIENCE INC - THERE WERE ONLY TWO EARLY
DISCONTINUATIONS
DUE TO AN ADVERSE EVENT, AND NO SERIOUS ADVERSE EVENTS WERE
REPORTED
    * DARE BIOSCIENCE INC - TOPLINE PK DATA FROM STUDY WILL BE
AVAILABLE LATER IN Q4 2022 AND WILL BE ANNOUNCED AT THAT TIME
    * DARE BIOSCIENCE INC - PLANS TO SUBMIT DATA FROM PHASE 1 /
2
CLINICAL STUDY OF DARE-HRT1 FOR PUBLICATION IN A PEER-REVIEWED
PUBLICATION

Source text for Eikon:  ID:nGNX1lLvqV 
Further company coverage:  DARE.O 
 ((Reuters.Briefs@thomsonreuters.com;))